Anal Cancer Clinical Trials 2023
Browse 38 Anal Cancer Medical Studies Across 198 Cities
5 Phase 3 Trial · 451 Anal Cancer Clinics
Discontinue PD-1/PD-L1-1 Inhibitorfor Bile Duct Cancer
9-valent HPV Vaccinationfor Human Papillomavirus
Concurrent Radiation Therapy, 5FU, Mitomycin And BMX-001for Anal Squamous Cell Carcinoma
Valproic Acidfor Viral Associated Cancer
Nivolumabfor Anal Canal Carcinoma
Proton Therapyfor Anal Cancer
Pembrolizumabfor Anal Cancer
HPV Specific T Cellsfor Anal Cancer
Endorectal Brachytherapyfor Rectal or Anal Cancer
Laboratory Biomarker Analysisfor Anal Cancer
What Are Anal Cancer Clinical Trials?
Anal cancer is cancer that occurs in the anus tissues. The majority of anal cancer is caused because of the human papillomavirus (HPV) infection. The primary signs and symptoms of anal cancer include a lump near the anus, rectal bleeding, pain and itching in the anus, mucus discharge, or bowel incontinence.
Why Is Anal Cancer Being Studied Through Clinical Trials?
Anal cancer is rare cancer and less common than rectum or colon cancers. Around 9,440 cases are estimated to occur in 2023, with a higher prevalence among women. The fatalities for anal cancer is 1,670. The lack of treatment options and research is an indication that there is a major need for anal cancer clinical trials and research to find a prevention or cure for this cancer.
What Are The Types of Treatments Available For Anal Cancer?
The treatment for anal cancer might vary depending on the severity and the symptoms experienced by the patient. Generally, anal cancer treatment involves a combination of chemotherapy and radiotherapy, known as chemoradiation.
Some other treatments for anal cancer might include radiotherapy and chemotherapy on their own, surgery, and lifestyle changes.
What Are Some Recent Breakthrough Clinical Trials For Anal Cancer?
2023: The findings of an experimental treatment for rectal cancer are being hailed as a significant breakthrough in recent years. In a small study at Memorial Sloan Kettering, patients were treated with dostarlimab for six months, and the results showed that every patient went into remission. No sign of cancer was found in the MRIs, endoscopies, physical examination, and other scans. In cancer research history, this happened for the first time ever when each participant went into remission after the treatment. This makes way for major interventions and treatment methods for cancer.
2023: The FDA has granted priority review for the combination of Trastuzumab and Tucatinib for treating colorectal cancer among individuals with unresectable or metastatic HER2-positive cancer. This review has been accepted on the basis of the promising results of the Mountaineer phase 2 trial, in which the combination of Trastuzumab and Tucatinib was found to be effective against this cancer compared to the individual dose of both medications. This is a major breakthrough since there are no current FDA-approved treatments or medications for colorectal cancer targeting HER2.
Who Are Some Of The Key Opinion Leaders / Researchers / Institutions Conducting Anal Cancer Clinical Trials Research?
Anal Cancer Foundation: This foundation empowers patients with anal cancer and accelerates the treatment and prevention methods to eliminate cancer, along with the HPV that is responsible for most cases. This is a non-profit, donor-supported advocacy, support, and research organization.
GI Cancers Alliance: This foundation focuses on fighting all gastrointestinal cancers, including anal cancer, by focusing on the voice and needs of the patient to address their unmet needs in treatment, awareness, and screening. The alliance raises awareness and funds to cure, treat and prevent GI cancers.